Dr. Roberto Valledor, MD
Family Medicine (Family Medicine Physician)
1612 N Conway Ave
Mission, TX 78572
Who else practices at this address →
Hidalgo County is a federal mental health shortage area. About shortage areas
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2021
Licensed in Texas since 2024, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2021Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
TX license V3130 (first issued 2024; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 9 payments worth $1,555 in total to this clinician.
| Madrigal Pharmaceuticals | $1,420 |
|---|---|
| Novo Nordisk Inc | $135 |
| Travel and Lodging | $1,045 |
|---|---|
| Food and Beverage | $510 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Madrigal Pharmaceuticals Oct 20, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $817 |
| Madrigal Pharmaceuticals Oct 20, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $228 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $168,955 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429 - A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05519475 - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.